MedTrace Logo

RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer

NCT05313906 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-04-06

No results posted yet for this study

Summary

To explore the safety and clinical efficacy of cisplatin combined with RC48 and anti-PD-1 antibodies AK105 in Her-2 positive advanced gastric cancer.

Conditions

  • Advanced Gastric Carcinoma
  • HER2-positive Gastric Cancer

Interventions

DRUG

RC48+AK105+cisplatin

RC48 plus AK105 and cisplatin

Sponsors & Collaborators

  • Rongchang Biopharmaceutical

    collaborator UNKNOWN

  • Zhengda Tianqing Pharmaceutical Group Co., Ltd.

    collaborator UNKNOWN

  • Henan Cancer Hospital

    lead OTHER_GOV

Principal Investigators

  • Quanli Gao, Dr · Henan Provincial People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-07
Primary Completion
2024-04-30
Completion
2024-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05313906 on ClinicalTrials.gov